Rapid Therapeutic Science Stock Return On Equity
| RTSL Stock | USD 0 0.00 0.00% |
Rapid Therapeutic Science fundamentals help investors to digest information that contributes to Rapid Therapeutic's financial success or failures. It also enables traders to predict the movement of Rapid Pink Sheet. The fundamental analysis module provides a way to measure Rapid Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rapid Therapeutic pink sheet.
Rapid |
Rapid Therapeutic Science Company Return On Equity Analysis
Rapid Therapeutic's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rapid Therapeutic Science has a Return On Equity of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
Rapid Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rapid Therapeutic's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rapid Therapeutic could also be used in its relative valuation, which is a method of valuing Rapid Therapeutic by comparing valuation metrics of similar companies.Rapid Therapeutic is currently under evaluation in return on equity category among its peers.
Rapid Fundamentals
| Return On Asset | -0.55 | |||
| Current Valuation | 13.08 M | |||
| Shares Outstanding | 7.75 M | |||
| Shares Owned By Insiders | 66.33 % | |||
| Price To Book | 136.70 X | |||
| Price To Sales | 193,667 X | |||
| Revenue | 534 | |||
| Gross Profit | 334 | |||
| EBITDA | (1.48 M) | |||
| Net Income | (2.87 M) | |||
| Cash And Equivalents | 112.16 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 150 K | |||
| Debt To Equity | 1.13 % | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0.40) X | |||
| Cash Flow From Operations | (2.21 M) | |||
| Earnings Per Share | (0.51) X | |||
| Beta | -10.77 | |||
| Market Capitalization | 4.22 M | |||
| Total Asset | 2.2 M | |||
| Z Score | 16.8 | |||
| Net Asset | 2.2 M |
About Rapid Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rapid Therapeutic Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rapid Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rapid Therapeutic Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.